Hexarelin vs Ipamorelin: Potency, Selectivity and Lab Handling

Quick answer: Hexarelin and ipamorelin are both synthetic agonists of the ghrelin receptor (GHS-R1a) that stimulate growth hormone release from pituitary cells. Hexarelin is a hexapeptide noted for high potency and for broader activity: it also raises ACTH, cortisol and prolactin in published studies, and it binds the scavenger receptor CD36 in cardiac tissue. Ipamorelin is a pentapeptide noted for selectivity: in the original characterization it released growth hormone without a significant rise in ACTH or cortisol. Potency and breadth on one side, selectivity on the other, is the core of the comparison.

The sections below cover structure, receptor pharmacology, the selectivity data, desensitization and laboratory handling. For laboratory research use only; not for human consumption.

Where each peptide comes from

Both compounds belong to the growth hormone-releasing peptide (GHRP) family, a lineage of small synthetic peptides that began with enkephalin-derived analogs in the late 1970s and led to GHRP-6. These molecules were found to act through a receptor distinct from the GHRH receptor; that receptor, GHS-R1a, was cloned in 1996, and its endogenous ligand ghrelin was identified in 1999.

• Hexarelin (examorelin) is a direct structural descendant of GHRP-6 in which the D-tryptophan at position 2 is replaced by D-2-methyl-tryptophan. The methyl group improves chemical stability and potency.
• Ipamorelin was reported in 1998 by Raun and colleagues as the first GHRP-receptor agonist with a selectivity for growth hormone release comparable to that of GHRH itself. It is a pentapeptide incorporating the non-natural residues aminoisobutyric acid (Aib) and D-2-naphthylalanine.

Hexarelin vs ipamorelin at a glance

Shared mechanism: GHS-R1a signaling

GHS-R1a is a G protein-coupled receptor expressed on pituitary somatotrophs and in the hypothalamus. Agonist binding activates Gq/11, which stimulates phospholipase C, generates IP3 and diacylglycerol, releases calcium from intracellular stores and activates protein kinase C. The rise in intracellular calcium triggers exocytosis of stored growth hormone.

This pathway is separate from, and complementary to, the cAMP-driven pathway used by GHRH. In pituitary cell and animal experiments, combining a GHS-R1a agonist with a GHRH analog produces a growth hormone response greater than the sum of the two alone. That is the rationale for paired formats such as the CJC-1295 no DAC + ipamorelin blend.

Potency

Hexarelin is consistently described as one of the most potent members of the GHRP family, producing larger peak growth hormone responses than GHRP-6 at equimolar exposure in several comparative studies.

For ipamorelin, the original paper provides direct figures. In primary rat pituitary cells, ipamorelin released growth hormone with an EC50 of about 1.3 nM, similar to GHRP-6 at about 2.2 nM, and with comparable maximal efficacy. In anesthetized rats and conscious swine its in vivo potency was likewise in the same range as GHRP-6. Ipamorelin is therefore not a weak agonist; its distinguishing feature lies elsewhere.

Selectivity: the defining difference

Ipamorelin

Earlier GHRPs, including GHRP-6 and GHRP-2, raise plasma ACTH and cortisol in addition to growth hormone. In the swine experiments reported by Raun and colleagues, ipamorelin did not: ACTH and cortisol levels were not significantly different from those observed after GHRH stimulation, even at exposures more than 200-fold above the ED50 for growth hormone release. Levels of FSH, LH, prolactin and TSH were also unaffected. This profile is why ipamorelin is described as the first selective growth hormone secretagogue and why it is widely chosen when an experiment needs to isolate the growth hormone response from adrenal-axis activation.

Hexarelin

Hexarelin shows the broader profile typical of the earlier GHRPs. Published studies report increases in ACTH, cortisol and prolactin accompanying the growth hormone response, an effect thought to be mediated at the hypothalamic level through arginine vasopressin and related pathways. For some research questions that breadth is a confound; for others, such as studies of how ghrelin-receptor agonists engage the hypothalamic–pituitary–adrenal axis, it is the property of interest.

Hexarelin and CD36

Hexarelin has a second, GHS-R1a-independent binding site. Photoaffinity labeling studies in the early 2000s identified the scavenger receptor CD36 as a hexarelin-binding protein in cardiac membranes. In isolated perfused rat heart preparations, hexarelin produced CD36-dependent changes in coronary perfusion pressure, and the response was absent in hearts from CD36-deficient animals. Related work has examined hexarelin in rodent ischemia–reperfusion models and in macrophage cholesterol-handling pathways.

This makes hexarelin a dual-target ligand, and it means that not every effect of hexarelin in a tissue preparation can be attributed to the ghrelin receptor. Ipamorelin has no comparable well-characterized second target, which is another aspect of its cleaner pharmacology. The peptide is available as a 5 mg vial: hexarelin.

Structural notes

The two sequences share a recognizable C-terminal motif, D-Phe-Lys-NH₂, which is common across the GHRP family and important for receptor activation. They differ in the aromatic core and at the N-terminus.

• Hexarelin retains the histidine N-terminus and the tryptophan-rich core of GHRP-6. The 2-methyl substitution on the D-tryptophan indole ring adds steric bulk that slows oxidative and enzymatic attack at that position.
• Ipamorelin replaces the tryptophan residues with a single D-2-naphthylalanine and opens with Aib, an α,α-disubstituted amino acid that resists aminopeptidases and restricts backbone flexibility. It was derived from GHRP-1 through systematic truncation and substitution.

Both peptides incorporate D-amino acids and a C-terminal amide, features that make them considerably more resistant to proteolysis than peptides built only from natural L-residues. Both are basic molecules, carrying positive charge on lysine and histidine at neutral pH, and both dissolve readily in water.

Desensitization

Sustained or closely repeated exposure to GHS-R1a agonists reduces the subsequent growth hormone response, a consequence of receptor internalization and downstream adaptation. The effect is best documented for hexarelin: studies of prolonged repeated exposure describe a partial attenuation of the growth hormone response over weeks, which reversed after a washout period. In rodent studies with ipamorelin, the growth hormone response to repeated stimulation was comparatively well maintained. For experimental design, this argues for attention to exposure intervals and for including time-matched controls whenever either compound is applied repeatedly.

Laboratory handling and concentration math

Both peptides are short, C-terminally amidated and supplied as lyophilized powder. Handling is conventional:

• Reconstitution: add diluent slowly down the vial wall and swirl gently until clear; see how to mix peptides with bacteriostatic water.
• Hexarelin math: 2 mL added to a 5 mg vial gives 2.5 mg/mL, or about 2.82 mM at 887.0 g/mol.
• Ipamorelin math: 2 mL added to a 10 mg vial of ipamorelin gives 5 mg/mL, or about 7.02 mM at 711.9 g/mol.
• Molar matching: because the molecular weights differ by about 25%, equal mass concentrations are not equimolar. Comparative experiments should match on a molar basis. The calculator helps with the conversions.
• Stability considerations: hexarelin contains two tryptophan-type residues, which are sensitive to light and oxidation; ipamorelin has none. Protect hexarelin solutions from light in particular.
• Storage: lyophilized vials at −20 °C for the long term; reconstituted solutions at 2–8 °C. See storing research peptides.

Identity and purity for each batch can be confirmed on the COA page. The observed mass distinguishes the two unambiguously: an [M+H]⁺ ion near m/z 888 for hexarelin and near m/z 713 for ipamorelin.

Which compound fits which experiment?

• Isolating the growth hormone axis: ipamorelin is the usual choice when ACTH, cortisol or prolactin changes would confound the readout.
• Maximal GHS-R1a stimulation: hexarelin suits experiments that call for a high-potency, high-efficacy reference agonist.
• Cardiac and CD36 research: hexarelin is the relevant tool; ipamorelin can serve as a GHS-R1a-selective comparator to separate receptor contributions.
• Receptor desensitization studies: hexarelin has the more extensive literature on attenuation and recovery.
• GHRH synergy studies: either can be paired with a GHRH analog; ipamorelin keeps the endocrine readout narrower.

Both peptides, along with related secretagogues, are listed in the shop. For an introduction to the category, see what research peptides are.

Frequently asked questions

Do hexarelin and ipamorelin act on the same receptor?

Yes. Both are agonists of GHS-R1a, the ghrelin receptor, and release growth hormone through calcium-dependent signaling in pituitary somatotrophs. Hexarelin additionally binds CD36, which ipamorelin is not known to do.

Which is more potent?

Hexarelin is generally regarded as the more potent and efficacious growth hormone releaser. Ipamorelin showed potency and efficacy close to GHRP-6 in the original rat pituitary cell assays, with an EC50 near 1.3 nM.

What does "selective" mean for ipamorelin?

It means the growth hormone response occurs without a significant accompanying rise in ACTH, cortisol, prolactin or other pituitary hormones. In the original swine study this held even at exposures more than 200 times the ED50 for growth hormone release.

Why is hexarelin used in cardiac research models?

Because it binds CD36 in cardiac and vascular tissue independently of the ghrelin receptor. Isolated rat heart experiments showed CD36-dependent responses to hexarelin, which opened a line of preclinical research separate from growth hormone release.